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Abstract
Background Amblyopia screening can target reduced visual acuity (VA), its refractive risk factors, or both. VA testing is
imprecise under 4 years of age, so automated risk-factor photoscreening appears an attractive option. This review considers
photoscreening used in community services, focusing on costs, cost-effectiveness and scope of use, compared with
EUSCREEN project Country Reports describing how photo- and automated screening is used internationally.
Methods A systematic narrative review was carried out of all English language photoscreening literature to September 10th
2018, using publicly available search terms. Where costs were considered, a CASP economic evaluation checklist was used
to assess data quality.
Results Of 370 abstracts reviewed, 55 reported large-scale community photoscreening projects. Five addressed cost-
effectiveness specifically, without original data. Photoscreening was a stand-alone, single, test event in 71% of projects. In
contrast, 25 of 45 EUSCREEN Country Reports showed that if adopted, photoscreening often supplements other tests in
established programmes and is rarely used as a stand-alone test. Reported costs varied widely and evidence of cost-
effectiveness was sparse in the literature, or in international practice. Only eight (13%) papers compared the diagnostic
accuracy or cost-effectiveness of photoscreening and VA testing, and when they did, cost-effectiveness of photoscreening
compared unfavourably.
Discussion Evidence that photoscreening reduces amblyopia or strabismus prevalence or improves overall outcomes is
weak, as is evidence of cost-effectiveness, compared to later VA screening. Currently, the most cost-effective option seems
to be a later, expert VA screening with the opportunity for a re-test before referral.
Introduction
Amblyopia is usually asymptomatic and treatment is much
more effective if carried out before the age of about 7 years
[1–3], so it fulfils many of the World Health Organisation
(WHO) criteria [4] as a target condition for screening.
Unscreened prevalence is ~3% [5–7] in Caucasian popula-
tions, while that of significant refractive error can be up to
16% [7, 8] because many children with refractive errors will
have normal best-corrected visual acuity (VA). Screening of
young children significantly reduces amblyopia prevalence
[5, 9] so it is recommended or mandated in many countries.
The US Preventative Services Taskforce [10] recom-
mends vision screening at least once in children aged 3–5
years to detect amblyopia or its risk factors, but did not find
sufficient evidence to determine the optimal screening
interval in these children or to recommend screening under
the age of 3 years [11].
It is still unclear how children should be screened to
achieve optimal visual outcomes while avoiding excessive
costs, false referrals, and unnecessary (or unnecessarily
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early) treatment. A review by Solebo et al. [12] concluded
4–5 years is the optimum age to offer whole population
screening for amblyopia, but explicitly excluded refractive
risk-factor screening.
Amblyopia screening either tests for low VA itself, or its
risk factors, or both. VA testing has proven efficacy
[6, 13, 14], but only becomes accurate (e.g. a logMAR
linear test with >95% testability) in most children at around
4–5 years of age [15] and requires highly skilled personnel.
If refractive amblyopia risk factors can be detected earlier
(especially significant hypermetropia, anisometropia or
astigmatism which are the more amblyogenic than myopia),
treatment can start quickly and may be easier, and some
cases of amblyopia and strabismus, can be prevented alto-
gether. Such better outcomes could aid the development of
literacy, motor or social skills.
However, evidence of long-term efficacy of risk-factor
screening compared to VA screening in reducing the long-
term prevalence of amblyopia is weak. More children will
have early risk factors than will ever become amblyopic,
because some will emmetropise out of early refractive errors
or will accommodate to overcome modest hypermetropia.
Of note, there is still no definitive study that has estab-
lished the relationship between the size and type of risk
factors in early childhood, and the increased odds of
developing amblyopia. Clinical consensus based on the best
published evidence drives guidelines and definitions of
referral thresholds [16, 17] but empirical evidence is scarce.
Screening for refractive risk factors can be semi-
automated using photo- or autorefraction and is possible
even in infancy. Each test is quicker and less skilled, so cost
per screen is low. This, and the potential for earlier referral,
might, superficially, be very attractive to commissioners.
Photoscreeners (e.g. Plusoptix™, SPOT™ and GoCheck
Kids™) generally test both eyes simultaneously from a
distance of 1m. Some detect ocular media opacities and
larger angle strabismus but may miss microstrabismus.
Autorefractors such as the Retinomax™, test one eye at a
time and cannot detect strabismus. There are also smart-
phone apps that families can use at home. Henceforward,
where discussion applies to the principle of automated
detection of refractive error in general, the term ʻphoto-
screening’ will be used, but when discussing specific studies
the precise method will be specified if relevant.
There is a large literature and large-scale marketing
advocating phototorefraction as a low-cost option, but costs
for photoscreening referrals are generally not loaded at the
screening stage. They occur post-referral, often not borne by
the screening funders. Overall long-term costs are potentially
much higher and difficult to compare with VA screening.
The EUSCREEN Study compares the cost-effectiveness of
different vision and hearing screening programmes from 45
countries, mostly in Europe, and presents a publicly available
model to assist with implementation, modification or disin-
vestment of screening programmes worldwide. During the
study it became clear that the way photoscreening is being
adopted does not reflect, or is necessarily supported by, the
literature. Some decisions do not seem to have been based on
any evidence of cost effectiveness in comparison to other
screening. This report systematically assesses whether the
published evidence of photoscreening reflects community
adoption in non-research contexts. Where possible we also
examined any evidence of costs and cost-effectiveness.
Methods
The primary aim was to report how photoscreening for
amblyopia risk factors is being applied in practice. A further
objective was to assess the quality of any reports of costs or
cost-effectiveness, whether used as a stand-alone test or
when added to other childhood screening batteries.
A systematic narrative review was designed and regis-
tered with PROSPERO [18], an international database of
prospectively registered systematic reviews in health and
social care. Two reviewers (AH, PM) selected the search
strategy and terms which are publicly available on the
PROSPERO website [18]. Online searches of MEDLINE,
EMBASE, PsycINFO via Ovid, CINAHL and The
Cochrane Library from 1980 were undertaken on Septem-
ber 10th 2018. The University of Liverpool orthoptic lit-
erature database [19] was used to search the British and
Irish Orthoptic Journal, American Orthoptic Journal, Aus-
tralian Orthoptic Journal, European Strabismus Association,
International Strabismus Association and the International
Orthoptic Congress full paper conference proceedings not
electronically listed.
We included full-text original articles in English (i.e. not
conference abstracts, opinion pieces, guidelines, editorials).
As equipment is usually developed and validated using
clinical or community populations, the initial search inclu-
ded all papers reporting photoscreening. After the primary
search we included those using, or assessing feasibility of,
photoscreening in unselected children under 7 years of age
in actual or potential community projects; specifically
searching for any papers where costs were explicitly men-
tioned. AH carried out the primary title stage extraction and
excluded publications that were not written in English,
letters, editorials, conference or poster abstracts and dupli-
cates. Abstracts from the remaining papers were screened
by two reviewers (AH and AC) independently of each
other. Non-commercially available methods; test develop-
ment; validation of tests and new equipment against each
other or against other methods of refraction; refractive error
prevalence studies; or those deriving or refining referral
criteria; and older and non-typically developing populations
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were excluded. Birefringence scanning for foveal fixation
[20], only recently commercially available, was not
considered.
Selection was carried out iteratively using the pre-
determined inclusion/exclusion criteria. Full texts were
obtained for the articles considered as relevant, potentially
relevant, or if doubt existed. Any disagreements between
reviewers were to be resolved by a third researcher at the
full paper stage if disagreement remained.
Data extraction for the full-text studies was carried out
by AH using a pre-prepared data extraction sheet using
criteria agreed by AH and AC. This included, but was not
limited to: study characteristics (author, year, country, study
type/design); characteristics of the screening programme
(including target condition(s), the study sample (e.g. age,
gender, ethnicity), tests undertaken as part of the screening,
location, and whether on an unselected population or a
targeted group. Where reported, outcomes (untestable
children, re-tests, sensitivity, specificity, positive predictive
value (PPV), negative predictive value (NPV), referral rate,
false positives and false negatives) and details of short- and
long-term costs were noted. Possible costs were recorded as
classified as in Table 1.
Cost not just mentioned in passing (statements such a
ʻthis is a low-cost method’ in a discussion, but with no
supporting data), were evaluated using the CASP Economic
Evaluation Quality Checklist [21]. A sample 20% of these
were cross-checked by a second researcher (AC). The
checklist authors do not recommend a formal score, but
suggest it is used as a guide to assess the rigour of the
evaluation. Articles were therefore assigned to an ordinal
quality scale depending on how many of the 12 items on the
checklist had a ʻyes’ response, even if a comment was made
such as ʻin part’ or ʻattempted’.
Within the EUSCREEN project, Country Representa-
tives have been collecting national and local data on vision
and hearing screening and have completed extensive ques-
tionnaires, containing 126 questions on vision screening
across 9 domains. Reports were prepared with detailed
information on societal background, general screening
programmes, vision screening programmes, protocols, out-
comes and costs in each country [22]. If photoscreening was
being used, the EUSCREEN team requested additional
details as necessary.
Results
The literature search returned 573 potential titles. Two
hundred and three were excluded at the title stage. From the
remaining 370 papers, 88 were considered within scope,
with disagreement on ten further abstracts. These 98 papers
were obtained for detailed examination. Both reviewers read
the disputed ten papers and after this process one or other of
the reviewers changed their opinion independently in the
light of additional detail, so a third reviewer was not
involved. At this stage 38 were excluded, resulting in 60
papers for inclusion (see Supplementary File for details of
exclusions).
Most studies did not report local or national screening
schemes as such. In the United States (US), some well-
established research groups (e.g. The Alaska Blind Children
Discovery (ABCD) group [23–32], groups in Tennessee
[33–39] and Pennsylvania [40–48] the multi-centre Vision
in Preschoolers (VIP) Group [49–54] have published many
papers developing the evidence-base on the most effective
photoscreening tests, their validation and refinement of
referral criteria. Fifty-five percent of the 370 abstracts
reviewed were from the US, 17% from Europe and 14%
from East Asia.
Implementation and outcomes of photoscreening
Fifty-five papers described the implementation and out-
comes from large-scale community screening, or screening
Table 1 Possible costs of screening to illustrate that cost savings in one
funding area may increase unrecognised costs in another.
Monetary costs
Equipment; units needed per service, initial purchase, insurance,
maintenance and planned ongoing replacement




Staff time to administer test
Monitoring/audit costs
Admininistration of records/databases
Cost of recall/re-test/following-up failed appointments
Referral and outcome feedback costs
Secondary diagnostic referral visit with an eye care professional
Total screening cost per case detected
Cost of follow-up of borderline/untestable children
Glasses
Patches
Total cost per case—referral to discharge
Total cost per false +ve—referral to discharge
Parental time off work
Family travel costs




Educational advantage/disadvantage from the condition or its
treatment
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carried out as a pilot or feasibility studies for potential
programmes (see Supplementary Table). Five further papers
[20, 55–58] specifically addressed cost-effectiveness from a
theoretical standpoint using published data. Thirty-nine
papers (71%) reported photoscreening used as a stand-alone
test, although the ABCD protocol used an additional brief
history and ʻwarning signs’ questionnaire for parents [24].
Only 13 (24%) studies directly compared different test
options [29, 49, 55–66]. Four (7%) reported schemes where
VA was the primary test, with photoscreening as an adjunct
or part of a test battery [65–68]. Of note, Matsuo et al. [65]
found adding autorefraction to VA testing at 3.5 years tri-
pled the referral rate, but only increased amblyopia detec-
tion by 0.3%, concluding it was not cost-effective. One
paper reported photoscreening as a primary test, with further
extended screening only who failed [69]. Lowry and
Campomanes found that repeating the photoscreening
before referral was found to reduce referrals [70].
The age of children tested varied considerably. Many
studies tested a wide age range. e.g. 6 months to 12 years
[71], 2–9 years [72], 1–5 years [25, 73], 2–6 years [74], 4–7
years [30], 8 months to 5 years [75], 2 and 4.5 years [76],
3–11 years [33] and within these samples, age distribution
often also varied. In many developing countries, without
established vision screening, charitable outreach photo-
screening may only ever be done once per community, so
children from infancy to adolescence were screened [77].
Many papers reported ʻpre-school’ children (~3–6 years
[24, 29, 50, 64, 65, 78–81], while others specifically tar-
geted infants and toddlers [31, 36, 82–86].
Sixty percent of the papers reported diagnostic ʻsuc-
cess’ in terms of accurate detection of risk factors, not
actual amblyopia or low vision, and only 13% reported
actual amblyopia detection [24, 57, 59, 60, 64, 65, 87].
The definition of risk factors varied as published guide-
lines and definitions, such as the AAPOS [16] or the
ABCD Group [28] recommendations, developed over
time, so comparisons across the years are difficult. Few
studies were able to assess the children with significant
bilateral hypermetropia (a major amblyopia risk-factor),
but who accommodated sufficiently to pass a brief pho-
toscreening [49, 88], but one study found that Plusoptix
photoscreening detected only one out of 13 children with
significant hypermetropia [60].
The reporting of follow-up rates, and particularly long-
term outcomes was often poor or absent. US studies, despite
great efforts to encourage follow-up and reporting, often had
disappointing follow-up rates of <40% [24, 29, 79, 89, 90].
Good rates of >70% were rare [60, 91, 92], so lack of data is
a barrier to any accurate long-term relative risk or cost-
effectiveness modelling [58, 71].
Untestable and inconclusive rates in young children were
often high. Longmuir et al. [91] reported 25% untestability
in 210,695 infants under 12 months and Hope et al. [61]
reported up to 24% untestability at 6–9 months. Many
screening programmes (especially if administered by lay
screeners), would advise a ʻrefer’ or ʻrecall’ decision for
untestable children.
PPVs even for risk factors, not actual amblyopia or
reduced vision, varied widely from 19% [85] to >80% [27],
but were generally lowest in the youngest children [90].
Referral rates were particularly high in very young children
e.g. 19% at 6–9 months [84], 20% at 9–36 months [83],
16% at <12 months [61], but often did not result in
immediate treatment. One study reported that only 11%
of 123 children under 36 months referred received
any intervention, compared to a 74% in children over
36 months [93].
Cost evaluations
Costs were considered in 23 (38%) of the 60 full papers
included (Table 2) and were mentioned in passing in a
further 16%. Similar findings appear in a paper and exten-
ded conference transaction [55, 56] so were considered
together. Only four papers addressed more than seven of the
12 CASP checklist items [20, 24, 56, 58]. Even if a
checklist item was given a ʻyes’, it was often only very
superficially addressed.
If actual costs were reported, they varied widely (see
Table 2). Nineteen papers reported from an actual screening
programme, while the remainder used modelling from data
from other sources. Only three of the 23 papers were from
outside the US (Germany [56], Belgium [83] and Japan
[67]) and six papers presented data from non-typical
settings e.g. Alaska, with a remote, sparse population
[24, 26, 31, 32, 62] or from a minority ethnic population at
higher risk of astigmatism [63].
Most only considered immediate costs: per test
[24, 26, 32, 36, 94–96], per case detected (usually cases of
risk-factor, not amblyopia) [25, 56, 57, 63, 70, 83, 95, 96], or
to diagnosis [56, 57, 63, 70, 83, 95, 96]. Longer-term costs
were more disparate: savings made by re-screening [57],
screening service cost [58, 63, 71], total cost to a state [73],
additional costs of adding photoscreening to established ser-
vices [24, 31, 56, 65], costs of different types of follow-up
[57], costs to third-party providers [24, 57, 63, 70], cost for
detection plus follow-up [57, 58, 70], lifetime costs e.g.
Quality Adjusted Life Years (QALYs) [20, 31, 71]. Cost-
effectiveness was the primary focus of only seven papers
[20, 24, 55–58, 63]. None addressed any potential cost ben-
efits associated with the earlier detection of wider refractive
error (as opposed to amblyopia) and any possible societal or
educational benefits from its correction. Regular maintenance
and replacement of relatively expensive photoscreeners within
long-term services were not considered.
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Eight papers attempted formal modelling [20, 24, 56–
58, 63, 70, 97]. Joish et al. [20] considered lifetime societal
costs in the US, using societal perspective decision-analytic
modelling based on published data, comparing VA screening
versus photoscreening at three different ages: 6–18 months,
3–4 years and 7–8 years. All scenarios were considered cost-
effective, with total net cost benefit at 3–4 years being highest
from photoscreening, but the cost-to-benefit ratio was highest
for VA screening at the same age. An important limitation
was that testing at 5–6 years was not considered, although this
is when VA testing is accurate, but children are still within the
critical period. They discussed the methodological difficulties
in using modelling approaches when evidence of the societal
significance of unilateral amblyopia or ʻpoor’ versus ʻgood’
eyesight (which presumably includes uncorrected refractive
error) is weak.
König and Barry [55, 56] used German data and
healthcare settings in a decision-analytic model (Monte
Carlo simulation) comparing five different amblyopia
screening modalities at age 3 years (different VA testing ±
orthoptic tests, and non-cycloplegic autorefraction) from a
third-party payer perspective, although they did not model
beyond diagnosis, or at different ages. They concluded that
ʻbecause of a great proportion of false negative, false
positive and inconclusive results, refractive screening was
less effective with an unfavourable cost-effectiveness’. This
paper is important because most literature agrees that VA
testing at 3 years of age can be imprecise, but even so,
autorefraction led to much higher cost per case of risk
factors detected (≈1500 Euros (€) versus €≈900 for VA
screening). They found that adding orthoptic tests to VA
testing made only small improvements in detected case
numbers. For all scenarios, re-screening inconclusive results
was more cost-effective than direct referral after a first
screening.
Rein et al. [58] used two US state screening pro-
grammes in probabilistic microsimulation modelling
considering lifetime per-person costs and QALYs gained.
They compared VA/stereopsis (VA/SV)) (Random Dot E
540″ pass/fail) screening at kindergarten (4–6 years) only;
similar screening twice at preschool and kindergarten; and
photoscreening in preschool and VA/SV screening in
kindergarten, but did not consider photorefraction as a
stand-alone test. All scenarios were considered cost-
effective compared to no screening, with increased
QALYs. Earlier photoscreening followed by later VA/SV
screening was the costliest option, for both amblyopia-
related treatment, and lifetime costs, but it might result
in greater long-term benefits than VA/SV screening in
preschool alone. Because evidence of actual QALYs lost
from amblyopia [98] is sparse, they modelled various
scenarios and found wide variations in QALYs driven by
different QALY weights and differences in treatment
efficacy. Replacing VA/SV in kindergarten with photo-
screening in the two-screenings scenario was the costliest
option, and only became more favourable when the
assumption of QALYs lost per year of impairment was
increased.
Miller et al. [63] used an economic model to estimate
different screening modalities, (including photoscreening),
among preschool children, when different size groups were
screened. They only considered the direct costs of the
screening and equipment itself, not of longer-term diag-
nosis, treatment or follow-up. VA screening was more cost-
effective for small populations, but automated methods
became relatively cheaper for larger groups. Although their
target group was a native American population with a high
prevalence of astigmatism, their conclusion that photo-
screening alone was generally not cost-efficient is likely to
also apply elsewhere.
Lowry and Campomanes [70] modelled the most
cost-effective autorefraction referral criteria to use in ʻpre-
schoolers’ (presumably 3–5 years) across different
refractive error risk-factor types. They compared the VIP
criteria [88], a local variation based upon them and
referral criteria derived from their modelling which would
pass more mild refractive errors. They concluded that
their own criteria (e.g. up to 3.25 D of anisometropia
compared with the VIP criterion of 2.00 D) would be more
cost-effective, but they stopped short of considering
treatment costs. They also pointed out that many factors
beyond their analysis might affect policy decisions in
different communities and healthcare models. They sub-
sequently used a retrospective cohort cost-effectiveness
and a decision-analytic model and probabilistic sensitivity
analysis of referrals from both VA and photoscreening in
Californian pre-schools [57]. They concluded that
community-based follow-up of referrals was a more cost-
effective than mobile clinics but did not analyse the costs
of the screening itself.
Arnold et al. [24] reported data from the Alaskan ABCD
programme using the MTI photoscreener. They used a
deterministic model for their simulation and considered the
societal cost per child with amblyopia risk factors over the
first 10 years of life. They used a cost-consequence method
using Reference-Case Analysis for photoscreening against
two established screening paradigms; the 1995 American
Academy of Pediatrics guidelines [99] which recommended
multiple assessments versus a ʻtrickle in’, unscreened,
situation, as well as estimates of costs of other US care
options. Cost per amblyopic child was ~40% higher in rural
communities, but overall, adding photoscreening increased
the (then) current screening costs by 9%, while complete
pre-kindergarten eye tests from an ophthalmologist would
add 49% to overall eye care US-wide. While clearly sup-
porting the use of photoscreening the authors did
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acknowledge that there are still many unknowns, particu-
larly in relation to the societal significance of unilateral
amblyopia.
Membreno et al. [97] used a cost-utility analysis from a
third-party insurer perspective using a decision analysis
modelling strategy to estimate costs of undetected
amblyopia to a US state as evidence to support a new
photoscreener programme. Amblyopia screening
was considered cost-effective in terms of QALYs com-
pared to no screening, but they did not compare alter-
native screening options.
EUSCREEN country report data
Twenty-five of the 45 countries (56%) returning the ques-
tionnaires [100] stated that photorefraction or automated
refraction was used to some extent in their country, but
national or large regional schemes utilising universal pho-
toscreening were unusual (e.g. Flanders in Belgium).
Country Representatives often struggled to access data
which was rarely publicly available. Fifteen countries used
Plusoptix photoscreening devices and the others used dif-
ferent (sometimes undefined) autorefractors such as Reti-
nomax, or a combination of methods.
Only Israel and Hungary reported that photorefraction
or automated screening was widely used as a stand-alone
test and in most countries it is administered by experi-
enced professional screeners. Most countries reported that
beyond neonatal screening, at least one other test is car-
ried out, generally involving a VA test and/or cover
testing and external examination. Photoscreening is often
a recent addition to existing services and there was no
evidence that since the advent of photoscreening, existing
services had been reduced or modified. Audit data was
rarely available or collected centrally. The Flanders region
of Belgium seems an exception [101] and wide within-
country variation was the rule. No country guidelines
have mandated photoscreening alone.
Photoscreening is often used to target young children
before VA tests are accurate; or for children untestable or
equivocal with a VA test; or only for private patients;
or in one case, only on older children looking for devel-
oping myopia. Ages varied widely: 6 months (1 country),
12 months (2 countries), 18 months (1 country), 3 years
(5 countries), 4 years (2 countries), and unspecified times
(13 countries). In some countries it was used repeatedly in
multiple screenings.
The weight given to the photoscreening also varied: one
country reported that if VA was within normal limits, but
photoscreening suggested a refractive risk-factor, the child
would still be referred. Elsewhere a child passing a VA test
would not be photoscreened at all, so would never be
referred for risk factors alone.
Photoscreening was used more widely if screening was
carried out by non-eye-specialist screeners, particularly
paediatricians or GPs e.g. Germany and the Czech Repub-
lic. Where private providers carried out screening, photo-
screening was more common and could incur additional
charges. Where it is offered by doctors with a higher level
of expertise and autonomy, the country representatives
found it more difficult to access data, and how photo-
refraction is used is more subject to professional discretion.
Discussion
Photoscreening is being widely adopted, and in many dif-
ferent ways, but with poor availability of local, regional or
national protocols, audit or monitoring of long-term out-
comes or costs. There is weak evidence of optimum timing,
frequency, or referral criteria to maximise outcomes whilst
minimising monetary and societal costs.
Despite published guidelines [16] there is still no clear
evidence what level of refractive error constitutes an
amblyopia risk-factor at different ages, or the optimum time
to treat risk factors. Commissioners have little evidence on
which to base difficult public health decisions and may be
unaware of the significant differences, in terms of relative
outcomes, costs or cost-effectiveness, between VA screen-
ing and photoscreening. Different reporting metrics make
comparisons very difficult. Issues arising from this review
highlight the relative advantages and disadvantages of
photoscreening compared to more conventional VA testing,
and some have significant cost implications.
The literature gives an impression that photoscreening is
commonly used as a stand-alone test, but the EUSCREEN
data shows that it is usually an addition to established
screening tests.
Early vs. late screening
The true prevalence and severity of amblyopia in very
young children is unknown because a definitive diagnosis is
not possible until VA can be tested, so risk-factor versus
amblyopia prevalence cannot be compared. The low treat-
ment rate in children under 36 months found by Halegoua
and Schwartz [93], suggests poor correlation between risk-
factor and amblyopia diagnoses.
Photorefraction is more testable than VA under 4 years
of age, so providing an opportunity for early intervention,
and is often thus promoted and marketed. The EUSCREEN
study shows it has been added to several existing screening
programmes, often for the younger age groups, but in dif-
ferent ways and rarely adopted nationally.
Early detection, treatment and possible prevention
[7, 102] are generally considered a good thing. However,
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there are also higher false positive, equivocal referral and
untestable rates in younger children [82, 83, 103] and
untestable children are often automatically referred [60].
Test–re-test variability can be high and differ between
risk factors [80, 104], but decisions are often based on
single tests.
Early referral, however, carries considerable additional
costs to health services, insurers and parents: more specialist
visits and glasses between referral and discharge, parental
work absence and travel costs. More children will be
referred without a genuine problem, and who may not
develop one. PPVs are lower for screening in infancy [103]
—even for risk factors, let alone amblyopia. Early referral
may not mean earlier (or any) treatment if those on treat-
ment are only observed before a decision to treat or dis-
charge is made [93]. Astigmatism in very young children is
a particular problem because it can resolve or change sig-
nificantly in the first years of life [105].
Evidence from Flanders in Belgium and Portugal shows
that early photoscreening can result in many more young
children being given glasses [82, 101]. In Flanders, the
number of 4-year olds wearing glasses rose from 4.7% in
2012 to 6.4% in 2017 after the introduction of photo-
screening but it is unknown how many cases of amblyopia
were prevented. Halegoua and Schwartz [93] found that
only 3.5% of the 8.5% failing photoscreening with
amblyopia risk factors had more than ʻmild’ amblyopia.
Most ophthalmologists would feel professionally bound
to follow referred children carefully, and prescription of
glasses might take place at a lower threshold than the risk-
factor referral criteria. Risk-factor thresholds and prescrib-
ing norms are arrived at from average values from surveys
of individual prescribing practices [106–109], and can differ
widely between professionals in the same country [107].
Diagnostic and prescribing decisions are rarely centrally
regulated [103] or recorded. For example, a 3-year-old child
may be referred with a photoscreened anisometropia of
2.25 D, which on cycloplegic refraction is found to be 1.75
D. Many professionals would give this child glasses, or at
least observe them carefully once referred, even if the ani-
sometropia might not now quite reach the risk-factor referral
threshold of 2.0 D difference. Other infants may emme-
tropise, but still be watched for years and only discharged
once VA is testable. Parental anxiety, loss of trust, and costs
of repeated follow-up for children eventually discharged
without treatment carry societal costs. Professionals in
stretched and scarce services do not want multiple false or
borderline referrals.
Accurate VA screening requires highly skilled testers,
longer testing times and is still imprecise under 4 years of
age. Referral may be later and outcomes may be worse in
terms of final VA [13], greater overall amblyopia pre-
valence, longer occlusion times [3], more decompensated
strabismus [110], but Donohue et al. [95] reporting
experiences of photoscreening from over 400,000 photo-
screenings, argue ʻSince a small delay in detecting
amblyopia probably has minimal to no effect on treatment,
a legitimate argument can be made to demand extremely
high specificity (i.e. 97% or more) for all vision screening
instruments used in healthy preschool populations’. Such
high specificity (and for risk factors, not amblyopia itself),
suggested by Donohue et al. is rare [32, 77]; most studies
report much lower [59, 61, 79, 85, 89, 92]. Although
autorefraction aged 2 can be the best predictor of mild-
moderate visual impairment aged 4.5 years, the PPV is
generally poor and it does not reduce the prevalence of
problems detected later [76].
The significance of slightly poorer outcomes, as long as
treatment still starts within the critical period (under about 7
years of age), is weak. Kirk et al. [31] describe one logMAR
line better from earlier detection (<2 years vs. 2–4 years) as
ʻsubstantial’, but the adverse effects of modest delay in
starting occlusion under the age of 6 years are less dramatic
than beyond 7 years [3]. Following a nationally advised
[111, 112] change from health centre tests at 3–4 years, to
school entry testing at 4–5 years, national audits by the
British & Irish Orthoptic Society [113, 114] suggest that it
did not result in worse overall visual outcomes but
increased the coverage and accuracy of the screening
dramatically.
Evidence that small visual deficits (especially mild uni-
lateral amblyopia) carry increased lifetime costs is weak,
although falling below certain thresholds e.g. for driving
standards, or extra educational support, might have sig-
nificance for a few. The evidence that one or two years
delay in starting treatment, provided it is before 7 years of
age, is surprisingly sparse and sometimes equivocal
[31, 115]. Carlton et al. [98] found poor evidence of long-
term impact of unilateral amblyopia and little research has
been carried out on the relative impact to families of early
vs. late referral if outcomes are comparable.
Financial considerations
Photoscreening may be easy, quick and cheap, but longer
follow-up [116] and glasses are expensive [117]. Accurate
VA screening takes longer and needs expert testers who
cost more, but savings are likely post-referral because PPV
is higher and treatment time reduced. Later referral gen-
erally means at least 1 year’s less hospital or ophthalmol-
ogist follow-up. Although it may mean patches worn in
school, many families find this easier anyway.
Cordonnier and Kallay [83] estimated that false referrals
of children between 9 and 36 months, and only up to the
first diagnostic visit, inflated the cost per screened child
significantly. Donohue and Johnson [103] question the
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justification for referral for astigmatism in children under 2
years of age due to high untestable and referral rates and
low PPV. These are significant considerations in countries
where access to specialist services is limited by distance,
ability to pay, or workforce availability. Kemper and Clark
[118] reported that most US family physicians would be
unlikely to adopt photoscreening if false positives were over
10%. A 2016 review does not recommended photoscreen-
ing [119].
Hybrid and multiple screening services, using photo-
screening for the youngest or selected children, followed by
acuity testing when older, may load costs onto both
screening and treatment stages so adding photoscreening to
other testing can be the least cost effective option
[56, 58, 65]. Hybrid schemes would only be justified if they
led to better outcomes. Any state-funded support for the
whole patient journey enforces hard choices, as with the UK
National Health Service [12] which has opted for a single
VA screen at 4–5 years. In the private medicine context,
insurers increase premiums if total treatment costs increase.
Technical aspects of photoscreening
Papers rarely report other disadvantages of photorefraction.
It may miss nystagmus, optic nerve or retinal pathology, or
small angle strabismic amblyopia, which VA testing would
detect. It is known to be least accurate in detecting and
quantifying hypermetropia [60, 120, 121], a major stra-
bismus and amblyopia risk factor [122]. Anisometropia can
be missed by uniocular autorefraction if children accom-
modate, and myopia can be overestimated [79, 123]. Eye-
lashes or the lids obscuring pupil margins can return false
astigmatism or anisometropia readings, and children with
particular combinations of iris and retina pigmentation may
be untestable. There are also differences in linear operating
range with large pupils [122] and in calibration factors
between ethnic groups [124]. Commercially sensitive soft-
ware algorithms derived from largely Caucasian popula-
tions may not apply globally and although referral criteria
can often be adjusted, background calculation of refractive
error cannot.
Target condition
A final issue is a lack of consensus about what the target
condition for vision screening should be [50]. Traditional
screening literature has targeted amblyopia and low vision,
but much of the photoscreening literature reports ʻsuccess’
as detection rates for risk factors for these conditions, not
the conditions themselves, with few comparisons [68].
There has been ʻmission creep’ from screening for
amblyopia and low vision into screening for significant
refractive error, whether amblyogenic or not. Refractive
error may be a public health issue itself, but most children
with milder refractive errors will not be amblyopic, while
some amblyopes will not have significant refractive error.
Detection of early refractive error seems desirable, espe-
cially in countries where myopia or astigmatism are major
public health concerns [125], especially now that myopia
treatments are available [126, 127]. But does refractive error
fit WHO criteria for screening? It is largely unpreventable and
for many children it may not cause significant harm if cor-
rected a little later. There is some evidence that treatment of
hypermetropia might improve visual and educational out-
comes [13, 128], but photoscreening is least effective for
detecting hypermetropia [60]. Can all health services cope
with high numbers of mostly mild visual deficits?
Summary
There is no doubt that amblyopia should be detected before
7 years of age, beyond which it becomes much harder to
treat, but from a public health viewpoint, the optimum
timing and nature of that screening is still not established.
Photoscreening complicates the issue by changing the target
condition from amblyopia to amblyopia risk factors, and by
allowing earlier testing. Currently, the most cost-effective
option seems to be a later, expert VA screening with the
opportunity for a re-test before referral [56].
Countries must decide what fits their population,
healthcare goals, workforce and funding models. There is a
need for clear evidence that the extra post-screening costs
incurred by photoscreening for risk factors, especially if
carried out on infants and very young children, are justified
by improved overall outcomes. Despite efforts to standar-
dise reporting [17], this is still not happening and it is a
major barrier for decision-makers trying to making sense of
the evidence. The EUSCREEN project aims to support
these decisions in the future.
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